Abstract
Multiple myeloma (MM) is a currently incurable malignancy of plasma cells. Malignant myeloma cells (MMCs) are heavily dependent upon the bone marrow (BM) microenvironment for their survival. One component of this tumor microenvironment, B-Cell Activating Factor (BAFF), has been implicated as a key player in this interaction. This review discusses the role of BAFF in the pathophysiology of MM, and the potential of BAFF-inhibitory therapy for the treatment of MM. Multiple studies have shown that BAFF functions as a survival factor for MMCs. Furthermore, MMCs express several BAFF-binding receptors. Of these, only Transmembrane Activator and CAML Interactor (TACI) correlates with the MMC’s capability to ligate BAFF. Additionally, the level of expression of TACI correlates with the level of the MMC’s BM dependency. Ligation of BAFF receptors on MMCs causes activation of the Nuclear Factor of κ-B (NF-κB) pathway, a crucial pathway for the pathogenesis of many B-cell malignancies. Serum BAFF levels are significantly elevated in MM patients when compared to healthy controls, and correlate inversely with overall survival. BAFF signaling is thus an interesting target for the treatment of MM. Several BAFF-inhibitory drugs are currently under evaluation for the treatment of MM. These include BAFF-monoclonal antibodies (tabalumab) and antibody-drug conjugates (GSK2857916).
Via Krishan Maggon
Citation: Blood Cancer Journal (2015) 5, e282; doi:10.1038/bcj.2015.3
B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?Published online 27 February 2015
OPEN
P J Hengeveld1 and M J Kersten1
1Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands
Correspondence: PJ Hengeveld, Department of Hematology, F4-224, Academic Medical Center, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands. E-mail: P.J.Hengeveld@amc.uva.nl
Received 3 November 2014; Revised 2 January 2015; Accepted 21 January 2015